47 results on '"Friedberg, Jonathan W."'
Search Results
2. Current directions in the treatment of classical Hodgkin lymphoma
3. Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma
4. Update on follicular lymphoma
5. Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis
6. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab‐refractory iNHL (COMPLEMENT A + B study)
7. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study
8. First‐line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)‐Medicare population‐based study
9. Efficacy of lenalidomide in high‐risk diffuse large B‐cell lymphoma
10. Second‐line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study
11. A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806
12. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis
13. Chemotherapy free treatment of indolent lymphoma
14. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma
15. Follicular lymphoma: State‐of‐the‐art ICML workshop in Lugano 2015
16. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106
17. Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost‐effective
18. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States
19. Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704
20. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era
21. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601
22. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era
23. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort
24. Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells
25. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States
26. Radiation for diffuse large B‐cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project
27. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433
28. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network
29. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States
30. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database
31. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study
32. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab
33. Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States
34. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era
35. Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease
36. Symptomatic intracardiac diffuse large B-cell lymphoma
37. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma
38. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas
39. Salvage Therapy in Hodgkin's Lymphoma
40. Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database
41. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease
42. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma
43. Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma
44. High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.
45. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
46. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project.
47. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.